One multicenterPhase II trial (NCT04302025) is evaluating the efficacy of 8 weeks of targetedtherapy (alectinib, entrectinib, vemurafenib, or cobimetinib) in patients withStage IB-IIIB NSCLC with various different molecular alterations(ALK-rearranged; ROS1-rearranged, NTRK-rearranged, and BRAF mutated). Here, ALK is linked to non-small cell lung carcinoma.